Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLiu, Yinliang-
dc.identifier.issn0975-1076 (Online); 0971-7544 (Print)-
dc.description.abstractWhen Pfizer patented its new discovery of second medical use of sildenafil globally for Viagra, it met extensive challenges in many countries, with reasons of, among others, obviousness and insufficient disclosure. As ruled by the courts or patent offices in several countries, patent claims should not go beyond what the inventor disclosed to the public, or it may violate the basic rationale of the patent system and be challenged. The story of the Viagra patent in China was uniquely significant. When the Patent Reexamination Board invalidated the Viagra patent, China received unusual criticism which believably imposed influence upon the judicial decisions. Transnational corporations and their agents were advised to respect and not try to interfere with administrative and judicial procedures in China, which might help establish a fair and efficient judicial system that would benefit both domestic and international parties in a long run. The reasons leading to such extensive failure of the Viagra patents in many countries, especially in a time of enhanced global IP protection are explored in this paper.en_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceJIPR Vol.18(6) [November 2013]en_US
dc.subjectIntellectual propertyen_US
dc.titleThe Tale of Viagra Patents: Comparative Studies of the Global Challenges in China and Other Countriesen_US
Appears in Collections:JIPR Vol.18(6) [November 2013]

Files in This Item:
File Description SizeFormat 
JIPR 18(6) 523-533.pdf103.55 kBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.